摘要
目的比较卡维地洛和美托洛尔治疗慢性心力衰竭患者的疗效和安全性。方法80例慢性心力衰竭患者以1∶1随机分为卡维地洛组(40例)和美托洛尔组(40例)测定治疗前后临床心功能分级,血压、心率、左心室功能及血糖、血脂水平及肾功能。结果两组治疗后心功能均改善,左心室射血分数增高,收缩末期容量降低(P<0.05)。治疗后,血糖、肌酐变化值卡维地洛组与美托洛尔组比较差异有统计学意义(P<0.05),而总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)变化值卡维地洛组与美托洛尔组比较差异无统计学意义。结论卡维地洛治疗慢性心功能不全,患者安全,疗效与美托洛尔相似,但前者对糖代谢和肾功能可能有益。
Objective To compare the effects of carvedivlol and metoprolol in patients with chronic heart failure （CHF） . Methods Eighty CHF paients were randomly allocated to receive carvedilol （carvedilol group ,40 ） or metoprolol （metoprolol group , n = 40） treatment. Clinical characteristics, NYHA -functional class, LV ejection fraction and serum biochemical changes were compared between the two groups before and affer treatment. Resnits Both therapeutic regimens sigificantly in proved patients＇ NYHA functional class, LV ejection fraction was increased in both groups and end -systolic volume was decreased （ P 〈 0. 05 ）. In carvedilol group , serum grucose and creatinine levels were significantly reduced as compared to the metoprolol group after treatment （ P 〈 0.05 ）. Conclusion Despite similar therapeutic effects in improving LV function, carvedilol has better effects on glucose metabolism and renal function than metoprolol in treating patients with chronic heart failure .
出处
《临床医学》
CAS
2008年第8期19-20,共2页
Clinical Medicine
